A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 204 participants.

Also called NCT07930507

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 204 participants (planned count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT07930507
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China, Hong Kong SAR China, Malaysia, South Korea, Thailand, Vietnam (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07930507. Randomized; quadruple masking; primary purpose treatment. Start 2026-12-21 (anticipated); primary completion 2027-10-11 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients
Condition
Hypercholesterolemia
Intervention (Drug)
Laroprovstat
Intervention (Drug)
Rosuvastatin 1
Intervention (Drug)
Rosuvastatin 2
Intervention (Drug)
FDC laroprovstat/Rosuvastatin 1
Intervention (Drug)
FDC laroprovstat/Rosuvastatin 2
Intervention (Drug)
Placebo to match rosuvastatin
Intervention (Drug)
Placebo to match laroprovstat or FDC laroprovstat/rosuvastatin
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct07930507
Content hash
e959f03fc40314988a41727dfed6066640ab058a074753a55aba0cb1d5774039